Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Charles River Labs (CRL) PT Raised to $301 at Credit Suisse
February 17, 2021 4:13 PM ESTCredit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.
The analyst comments "CRLs 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It... More
Charles River Laboratories (CRL) to Acquire Cognate BioServices for $875 Million
February 17, 2021 7:07 AM ESTCharles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions.
James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, Cognate BioServices presents a unique opportunity to expand into a high-growth,... More
